Livzon Pharmaceutical to overhaul governance, board structure

Livzon Pharmaceutical Group has scheduled its 2025 First Extraordinary General Meeting for December 10, 2025, to vote on comprehensive governance changes. These include the proposed cancellation of the Supervisory Committee, with its functions to be absorbed by an enhanced Audit Committee. The company also seeks to amend its Articles of Association, Rules and Procedures for General Meetings, Rules and Procedures for Board Meetings, and Administrative Measures for the Use of Raised Funds.

A key agenda item for the EGM is the appointment of Wang Zhiyao as an independent non-executive director, who will receive an annual director fee of RMB120,000. These proposed amendments aim to streamline operations, bolster corporate governance, and align with updated regulatory requirements, ensuring robust oversight of the company's financial and operational activities.